Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Upstream Bio, Inc.
UPB · SEC Filings
website
75
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innova...
Price
3.58
Market Cap
196.08 M
Float
35.65 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about UPB
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Upstream Bio, Inc.
UPB · SEC Filings
35.65 M
Float
3.58
Price
196.08 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 13, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 26, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 5, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 6, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Sep 1, 2026
8-K
Upstream Bio Reports Q2 2026 Financial Results and Progress Toward Phase 3 Trials
Aug 11, 2026
8-K
Upstream Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jun 10, 2026
8-K
Upstream Bio Reports Q1 2026 Financial Results and Progress on Verekitug Clinical Programs
May 13, 2026
8-K
Upstream Bio, Inc. Enters into $150 Million "At-the-Market" Equity Offering Program
Mar 26, 2026
8-K
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports 2025 Financial Results
Mar 26, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
March 2026 ATM | Offering amount: $150,000,000 | Bank: Leerink Partners LLC
Mar 26, 2026
424B4
OFFERING | Shares amount: 15,000,000 | Share price: $17.00 | Offering amount: $255,000,000.00
Oct 11, 2024
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 26, 2026
S-3ASR
November 2025 SHELF
Nov 5, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 12, 2025
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Oct 11, 2024
S-1MEF
INITIAL REGISTRATION FOR OFFERING | Shares amount: 2,875,000
Oct 10, 2024
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
Oct 8, 2024
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 16, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 16, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 17, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 17, 2025
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G/A
FMR LLC (Filed by)
Nov 6, 2026
SCHEDULE 13G/A
Decheng Capital Global Life Sciences Fund IV, L.P. (Filed by)
Oct 29, 2026
4
GRAY MICHAEL (Reporting)
Sep 17, 2026
4
Ambrose Allison (Reporting)
Sep 17, 2026
4
Deykin Aaron (Reporting)
Sep 17, 2026
4
Sutherland Everett Rand (Reporting)
Sep 17, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Oct 11, 2024
CORRESP
Form CORRESP - Correspondence
Oct 8, 2024
CORRESP
Form CORRESP - Correspondence
Oct 8, 2024
CORRESP
Form CORRESP - Correspondence
Sep 30, 2024
CORRESP
Form CORRESP - Correspondence
Sep 18, 2024
LETTER
Form UPLOAD - SEC-generated letter
Aug 20, 2024
